- 8017 Labana Ct, Canton Township, MI 48187
- +1 (734) 418 2537
- info@a2zbillings.com
Dermatology runs more procedures per encounter than almost any other outpatient specialty. A single office visit can move from an evaluation to a biopsy, a destruction, and an excision on three different lesions, and each procedure carries its own code family, its own technique requirement, and its own medical-necessity standard. A biopsy billed by the wrong technique, a destruction counted against the wrong lesion type, or a claim that reads cosmetic instead of medical can hold up payment for care that was clearly warranted.
Excision and destruction codes are chosen by size and margin measured before anesthesia, not after, and Mohs surgery adds its own layer: staging, tissue block counts, and a requirement that the operating physician personally perform or directly supervise tissue processing at every stage. Biologics for psoriasis, eczema, and hidradenitis suppurativa bring dose-specific billing and heavy prior authorization on top of the procedural coding. A2Z Billings works with solo dermatology practices, multi-provider groups, and Mohs surgery centers across the United States.
Four issues shape reimbursement in dermatology, and general coding knowledge alone does not solve them.
A shave biopsy, a punch biopsy, and an incisional biopsy are three different codes, not one code applied loosely. Destruction codes shift again by lesion type and count. Picking the code from habit instead of the operative note is where reimbursement gets lost.
Biopsy, destruction, and excision often happen on different lesions in the same encounter, and each pairing has its own bundling rule.
Lesion removal, phototherapy, and laser treatment sit in a gray zone payers read as cosmetic unless the note documents a real symptom.
Psoriasis, eczema, and hidradenitis suppurativa biologics carry high drug costs and heavy step-therapy and severity-score requirements before approval.
Most denials in this specialty trace back to a short, repeatable list of coding and documentation gaps.
Destroying the remaining tissue at the same lesion after a biopsy is included in the biopsy code, not billed as a second procedure.
Excision and destruction codes depend on lesion size and margin recorded before injection; once tissue is numbed and prepped, the measurement runs too large.
A biopsy or excision claim without a linked pathology report reads as incomplete and draws review before it draws payment.
Appending modifier 25 to nearly every visit signals overuse to a payer; it only belongs on a truly separate, documented E/M service.
Current documentation rules require the operating physician to have personally performed or directly supervised tissue processing at each stage, or the stage does not hold up.
Lesion removal or laser treatment charted without a documented symptom like bleeding or irritation gets read as elective and denied.
Procedure codes come from CPT, maintained by the AMA, and diagnoses from ICD-10-CM. These are examples, not a full set, and the right code always depends on the technique performed and the tissue documented.
Documentation carries more weight than the code itself. Payers expect lesion size and margin recorded before anesthesia, the biopsy technique named rather than assumed, a linked pathology report for biopsy and excision claims, the destruction method and lesion count specified, and, for Mohs surgery, the stage sequence and supervision documented. When these elements are consistent, claims hold up under review. When they are thin, a specialty built on high procedure volume turns small gaps into large recoupments fast.
Dermatology visits run more procedures per encounter than most specialties, so a small error rate compounds fast across biopsies, destructions, and excisions. We verify and code before the claim goes out, and we trace every denial back to what caused it.
Verify whether the visit is covered as medical care or falls under a cosmetic exclusion before it is scheduled.
Match biopsy technique, destruction count, and excision size to the documented procedure and pathology report.
Submit severity scores and step-therapy records for biologics and other high-cost treatments before the first dose.
Work denials by reason code, post against contracted rates, and track AR before filing limits close.
We treat dermatology billing as its own procedure-heavy discipline, not a smaller version of general medical billing.
From eligibility and prior auth through biopsy, destruction, excision, and Mohs coding to denial recovery, every step is tuned to how a dermatology visit is actually documented and billed.
Severity scoring, step-therapy documentation, and dose-specific accuracy for biologics used in psoriasis, eczema, and HS.
Every biopsy and excision claim linked to its pathology report before the claim goes out.
Stage sequencing, tissue block counts, and supervision documentation matched to the operative note.
Denials traced to their source and fixed as a pattern, not resubmitted one at a time.
Biopsy is split by technique: 11102 for a shave or tangential biopsy, 11104 for a punch biopsy, and 11106 for an incisional biopsy, each with its own add-on code for extra lesions. Destruction runs 17000 through 17004 for premalignant lesions like actinic keratoses and 17110 through 17111 for benign lesions. Excision is 11400 through 11446 for benign lesions and 11600 through 11646 for malignant ones. Mohs surgery uses 17311 through 17315. The right code always depends on the technique used and the tissue removed.
If a lesion is biopsied and the remaining tissue is destroyed at the same visit, only the biopsy is billed; destruction of the biopsy site is bundled into it. If the destruction happens on a separate lesion during the same visit, both procedures can be billed with the correct modifier to show they were distinct sites. Mixing these up is one of the most common bundling errors in the specialty.
The first stage is billed as 17311 for the head, neck, hands, feet, or genitalia, or 17313 for the trunk, arms, or legs. Each additional stage at the same site is 17312 or 17314. An add-on code, 17315, covers each extra tissue block beyond the first five in any stage. Current documentation standards also require the operating physician to have personally performed or directly supervised the tissue processing for every stage billed.
These medications carry some of the highest per-patient drug costs in dermatology, so payers require proof before they approve them: typically a documented severity score, evidence that lower-cost topical or systemic treatments were tried first, and a specific diagnosis that matches the drug's approved use. That paperwork repeats at each reauthorization, not just at the first approval.
Payers look for a documented symptom, bleeding, irritation, pain, or functional impairment, rather than an appearance concern alone. A lesion removal or laser treatment note that only describes how a lesion looks, without a symptom tied to it, is read as cosmetic and denied regardless of the physician's clinical judgment.
They expect the lesion size and margin measured before anesthesia, the destruction method named (cryosurgery, electrosurgery, laser, or chemical), the lesion type and count, and, for excisions and biopsies, a pathology reference. Claims that carry these details consistently move through review faster and get downcoded less often.
Yes. Teledermatology, whether it is a live video visit or a store-and-forward image review, bills under standard evaluation and management or consultation codes with the correct place of service and telehealth modifier. Coverage and reimbursement rules for store-and-forward review in particular vary by payer, and we bill each visit to match current requirements.
If cosmetic-necessity denials, biopsy and destruction bundling errors, Mohs stage documentation, or biologic prior authorization are slowing payment at your practice, we can review your current billing and show where revenue is being lost.
